Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Aug 09, 2023 12:48pm
No Volume
Well back from vacation, does not look like I missed anything. Still no third party peer review on phase 2. The last 3 press releases were solid and very positive. I am flabbergasted that we never got
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 31, 2023 6:02pm
New Press Release - Arch Biopartners Engages Independent Trading Group as Market Maker
TORONTO, July 31, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has engaged the services of Independent Trading Group (“ITG”) to provide market-making services in accordance with TSX Venture Exchange (TSXV...
read article.
Fresh Insight into the Topaz Helium Project's Expected Size and Scale
posted Apr 26, 2024 9:00am by
Pulsar Helium Inc.
-
|
The prospective zone is very broad. We believe its not just an isolated occurrence but is actually something quite regionally extensive ...read more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 24, 2023 11:00am
Update
Last week Arch management did a webinar review of the past 12 months. The webinar was useful in the sense that it highlighted the milestones achieved in the past 12 months and outlined the future
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Comment by
Viking2233
on Jul 16, 2023 9:56am
RE:RE:Shorts
Tech Titan, there is a simple reason you have zero likes since your inception, you have nothing of value to add. Why are you even viewing this board? Why would you comment on this board. It is
...more
(1)
•••
TechTitan
X
View Profile
View Bullboard History
Comment by
TechTitan
on Jul 14, 2023 11:51pm
RE:Shorts
"Fingers crossed CIBC and Scotia shorts are gone"...Why post your tears here for them to read? $10 a share!? Then $50+ a share!??? Haha Wow! Get real and look at that chart. This can
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 14, 2023 9:06am
Shorts
Well not much happening here during middle of summer. We continue to eagerly wait for the 3rd party data review of phase 2 trial. I have noticed a difference in trading the past 5 days. The volume is
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 05, 2023 1:53pm
Interesting day of trading
So we open up at $2.05 and CIBC quicklyknocks it down to $2 but suddenly Anonymous shows up on scene and starts buying aggressively here driving us up to $2.14, thats a big swing. CIBC is hanging
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 02, 2023 9:31am
Co-ordinated Short Attack
Happy Canada Day! It is abundantly clear that there is a co-ordinated short attack being utilized against ARCH. It is frustrating that bonafide solid news released over the padt few months has had
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 30, 2023 9:04am
Raymond James Analyst
One needs to consider that our one sole analyst from Raymond James has been waiting for the release of independent third party review report on phase 2 trial. Now we know Health Canada has seen data
...more
(2)
•••
2019champs
X
View Profile
View Bullboard History
Comment by
2019champs
on Jun 29, 2023 8:19pm
RE:Fire Sale
The data is long overdue. Once P2 data is released and if analysts find it promising, we will likely get an upgrade on the stock. This will open up alot of buying opportunities. Hopefully we aren'
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 29, 2023 3:11pm
Fire Sale
Time to add more. Month end here, margin calls triggered. This is such a screaming buy, so undervalued, to have FDA approval for AKI phase 2 trial this should be up 100% minimum. We should be at $10
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 28, 2023 8:31pm
Somethings smells here
Yesterday's new release of FDA approval for AKI phase 2 trial should have caught the attention of any interested investors. IMO yesterdays news should have got us back up to $5 with high volume
...more
(325)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jun 27, 2023 5:32pm
Wild Ride Today
Well I told everybody to buckle up and you sure beeded your seat belt today. $2:14 to $2.38 in the first hour then the shorts stepped back in and quickly knocked in back down to $2.18. We slowly
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Comment by
Riverfolk
on Jun 27, 2023 10:17am
RE:News - ARCH BIOPARTNERS RECEIVES PERMISSION FROM U.S. FDA
Recent funding contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) announced by the Company in March 2023, will significantly help cover
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study